Search

Displaying results 2521 - 2530 of 10000 in total
  1. Indication

    Ariboflavinosis

    go.drugbank.com/conditions/DBCOND0020583
    Drugs: Riboflavin
    Synonyms: Vitamin deficiency: [B-complex deficiency NOS] or [ariboflavinosis] or [B12 nutritional deficiency NOS]
  2. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age...

  3. Indication

    Menkes Disease

    go.drugbank.com/conditions/DBCOND0042586
    Drugs: Copper histidinate
    Synonyms: Copper transport disease, X-linked copper deficiency
  4. Drug

    Casirivimab

    go.drugbank.com/drugs/DB15941
    ApprovedInvestigational

    [A221495] On November 21 2020, the FDA authorized emergency approval of REGEN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.

  5. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries

  6. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  7. Drug

    Aldoxorubicin

    go.drugbank.com/drugs/DB06013
    Investigational

    Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

  8. Drug

    MC-1

    go.drugbank.com/drugs/DB05315
    Experimental

    Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

    Synonyms: MC-1
  9. Drug

    Abametapir

    go.drugbank.com/drugs/DB11932
    Approved

    [A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … The improved ovicidal activity (90-100% _in vitro_) of abemetapir allows for a single administration, in contrast to many other topical treatments, and its novel and relatively non-specific mechanism may

  10. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk